KCT0006785已完成未知
Open-label, multicenter phase II study of imatinib mesylate (Leukivec®) in patients with steroid-refractory chronic graft-versus-host disease
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20?(Year) 至 70?(Year)（—）
- 性别
- All
入选标准
- •i) age = 20 years,
- •ii) Eastern Cooperative Oncology Group performance status score = 2,
- •iii) Chronic graft-versus host disease that meets the NIH diagnostic criteria after allogeneic-SCT,
- •iv) moderate or severe cGVHD based on the NIH global scoring system,
- •v) steroid-refractory cGVHD,
- •vi) resistance to calcineurin inhibitors such as cyclosporine and tacrolimus
排除标准
- •1. Hepatic chronic graft-versus host disease alone
- •2. Patients who had donor lymphocyte infusion
- •3. Poor general condition
- •4. ECOG > 3
- •5. Other investigational agent treatment
研究者
相似试验
进行中（未招募）
不适用
An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumorsmalignant nerve sheath tumorEUCTR2005-004774-24-DEovartis Pharma GmbH
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
进行中（未招募）
不适用
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240
招募中
2 期
A randomised phase II trial of imatinib alternating with;regorafenib compared to imatinib alone for the first line ;treatment of advanced gastrointestinal stromal tumour (GIST)GISTgastrointestinal stromal tumour10072990NL-OMON56311European Organisation for Research in Treatment of Cancer (EORTC)18
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)EUCTR2015-001298-42-FREuropean Organisation for Research and Treatment of Cancer240